S

Shanghai MicroPort EP Medtech Co Ltd
SSE:688351

Watchlist Manager
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Watchlist
Price: 20.15 CNY 0.85% Market Closed
Market Cap: 9.5B CNY
Have any thoughts about
Shanghai MicroPort EP Medtech Co Ltd?
Write Note

Shanghai MicroPort EP Medtech Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicroPort EP Medtech Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Accrued Liabilities
ÂĄ35.2m
CAGR 3-Years
47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Accrued Liabilities
ÂĄ132.8m
CAGR 3-Years
41%
CAGR 5-Years
42%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Accrued Liabilities
ÂĄ321.1m
CAGR 3-Years
38%
CAGR 5-Years
42%
CAGR 10-Years
49%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Accrued Liabilities
ÂĄ3.9B
CAGR 3-Years
24%
CAGR 5-Years
23%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Accrued Liabilities
ÂĄ116.9m
CAGR 3-Years
55%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Accrued Liabilities
ÂĄ879.6m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort EP Medtech Co Ltd
Glance View

Market Cap
9.5B CNY
Industry
Health Care

Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.

Intrinsic Value
7.2 CNY
Overvaluation 64%
Intrinsic Value
Price
S

See Also

What is Shanghai MicroPort EP Medtech Co Ltd's Accrued Liabilities?
Accrued Liabilities
35.2m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicroPort EP Medtech Co Ltd's Accrued Liabilities amounts to 35.2m CNY.

What is Shanghai MicroPort EP Medtech Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
47%

Over the last year, the Accrued Liabilities growth was 37%. The average annual Accrued Liabilities growth rates for Shanghai MicroPort EP Medtech Co Ltd have been 47% over the past three years .

Back to Top